Core Viewpoint - The company, Shanghai MicroPort MedBot (Group) Co., Ltd., will participate in the 2024 annual performance briefing for the medical device industry organized by the Shanghai Stock Exchange, aiming to provide investors with insights into its 2024 operational results and financial status [2][3]. Group 1: Event Details - The investor briefing will be held on April 25, 2025, from 15:00 to 17:00, in an online interactive format via the Shanghai Stock Exchange Roadshow Center [6][7]. - Investors can submit questions in advance until April 24, 2025, at 16:00, either through the Roadshow Center or via the company's email [5][6]. Group 2: Participants - Key participants in the briefing include Dr. Zhu Qing (CEO), Mr. Ye Xiaojie (Independent Director), Mr. Liu Hao (Vice President of Treatment Solutions), Mr. Qiu Genyong (Vice President and Board Secretary), and Ms. Li Chunfang (Senior Financial Director) [4]. Group 3: Contact Information - For inquiries, investors can contact the Board Office at 021-38139300 or via email at irm@endovastec.com [8].

证券代码：688016 证券简称：心脉医疗 公告编号：2025-021 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2025 年 4 月 25 日（星期五）下午 15:00-17:00 上海微创心脉医疗科技（集团）股份有限公司 关于参加 2024 年度科创板医疗器械行业集体业绩说 明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"）已于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年年 度报告，为便于广大投资者更全面深入地了解公司 2024 年年度经营成果、财务 状况、发展理念，公司参与了由上海证券交易所主办的 2024 年度科创板医疗器 械行业集体业绩说明会，此次活动将采用网络文字互动的方式举行， ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly on innovative drugs and their internationalization process, while suggesting a focus on blood products and scientific instruments in the short term [4][18]. Core Insights - The pharmaceutical sector has shown stable stock performance, with significant approvals for innovative drugs such as the IL-21/IL-23 dual antibody by Kangfang Biopharma and the successful phase 3 clinical trial results for Eli Lilly's orforglipron [1][2][18]. - The report emphasizes the resilience and growth potential of the pharmaceutical sector amidst changing external tariff environments, highlighting low geopolitical risks for innovative drugs and opportunities for domestic replacements in blood products and medical devices [4][18]. - The report suggests a continuous focus on innovative and semi-innovative drug companies, as well as potential recovery in the performance of generic drugs, chain pharmacies, and traditional Chinese medicine post-Q1 reports [4][20]. Summary by Sections Pharmaceutical Sector - Kangfang Biopharma's IL-21/IL-23 dual antibody has been approved for moderate to severe plaque psoriasis, marking a significant milestone as the first domestic drug of its kind [19]. - The approval of AstraZeneca's capivasertib for second-line breast cancer treatment further highlights the growing number of innovative drugs being approved in China [23][25]. - The report anticipates a surge in licensing transactions as Chinese innovative drug assets mature, leading to more predictable performance for pharmaceutical companies [2][25]. Biological Products - Eli Lilly's orforglipron has successfully completed phase 3 clinical trials, demonstrating superior A1C reduction compared to placebo, which positions it as a leading oral GLP-1 receptor agonist [26][29]. - The report encourages monitoring the progress of domestic GLP-1 small molecules, which are showing promising clinical results [33][34]. Medical Devices - Domestic companies are making significant strides in innovative research and development, with products like the LiqMagic peripheral vascular shockwave treatment system gaining traction in clinical applications [35][36]. - The report notes that the innovative technology in vascular treatment is expected to enhance patient outcomes and reduce procedural risks [35][36]. Investment Recommendations - The report recommends focusing on innovative and semi-innovative drug companies such as Kelun-Biotech, Kangfang Biopharma, and Huadong Medicine, as well as blood products and scientific instruments for potential domestic replacements [5][20]. - It also suggests paying attention to the recovery of generic drugs, chain pharmacies, and traditional Chinese medicine as the market stabilizes post-Q1 [4][20].

证券代码：688016 证券简称：心脉医疗 公告编号：2025-020 上海微创心脉医疗科技（集团）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年4月18日 （二）股东大会召开的地点：上海市浦东新区康新公路3399弄25号楼9层公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 1、公司在任董事7人，出席7人； 2、公司在任监事3人，出席3人； 3、公司董事会秘书出席了本次会议；公司部分高管列席了本次会议，见证律师见证了本次会议。 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于公司《2024年年度报告》及其摘要的议案 ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会采用现场投票和网络投票相结合的方式召开，会议由董事会召集，董事长Jonathan Chen先 生主持，本 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-020 上海微创心脉医疗科技（集团）股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （二） 股东大会召开的地点：上海市浦东新区康新公路 3399 弄 25 号楼 9 层公 司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 157 | | --- | --- | | 普通股股东人数 | 157 | | 2、出席会议的股东所持有的表决权数量 | 52,339,749 | | 普通股股东所持有表决权数量 | 52,339,749 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 43.1579 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 43.1579 | （四） 表决方式是否符合《公司法》 ...

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2024 年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）根据 《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市规则》和 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规定对 上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗"、"公司" 或"上市公司"）进行持续督导，并出具本持续督导跟踪报告。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体的 | 保荐机构已建立并有效执行 | | | 持续督导工作制定相应的工作计划 | 了持续督导制度，并制定了 | | | | 相应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前，与 | 保荐机构已与公司签订《保 | | | | 荐协议》，该协议明确了双 | | | 上市公司或相关当事人签署持续督导协议，明确双方在 | 方在持续督导期间的权利和 | | | 持续督导期间的权利义务 ...

致:上海微创心脉医疗科技(集团)股份有限公司 北京市嘉源律师事务所 北京市嘉源律师事务所 关于上海微创心脉医疗科技(集团)股份有限公司 2024 年年度股东大会的法律意见书 -- Ph W OFFICES 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 师语音音 所 N LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 关于上海微创心脉医疗科技(集团)股份有限公司 2024年年度股东大会的法律意见书 嘉源(2025)-04-217 北京市嘉源律师事务所(以下简称"本所")接受上海微创心脉医疗科技(集 团)股份有限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》 (以下简称"《公司法》"》《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《上海微创心脉医疗科技(集团)股份有限公司章程》(以下简称"《公司章 程》")的有关规定,指派本所律师对公司 2024年年度股东大会(以 ...

Core Viewpoint - The company, Shanghai MicroPort CardioFlow Medtech Co., Ltd., is experiencing a decline in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential undervaluation in the context of its financial performance and market position [1][2]. Company Overview - The main business of the company includes the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2]. - Key products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, and various types of stents and balloons [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.206 billion yuan, representing a year-on-year increase of 1.61% [2]. - The net profit for the same period was 502 million yuan, reflecting a year-on-year growth of 1.96% [2]. - The gross profit margin stands at 73.01%, indicating strong profitability [2]. Market Position - As of the latest data, the company's rolling PE ratio is 21.19, significantly lower than the industry average of 45.94 and the median of 29.64, positioning it at 47th among its peers [1][3]. - The total market capitalization of the company is approximately 10.639 billion yuan [1]. Institutional Holdings - A total of 259 institutions hold shares in the company, with 253 being funds, 4 others, 1 brokerage, and 1 social security fund, amounting to a total holding of 73.239 million shares valued at 8.045 billion yuan [1].

上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清入选"明珠领军人才"，刘梦钦、王金耀、 屠春霖、樊亚明入选"明珠工程师"。 最新一期业绩显示，2024年年报，公司实现营业收入12.06亿元，同比1.61%；净利润5.02亿元，同比 1.96%，销售毛利率73.01%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)48心脉医疗21.9121.912.90110.00亿行业平均 46.1548.384.77102.50亿行业中值29.1 ...

Summary of Key Points Core Viewpoint - The company, Xinmai Medical, is actively engaging in share repurchase programs and preparing for its annual shareholder meeting, indicating a focus on shareholder value and financial performance. Trading Information - On April 3, 2025, Xinmai Medical's stock closed at 97.52 yuan, down 0.88%, with a turnover rate of 2.74% and a trading volume of 33,800 shares, amounting to a total transaction value of 331 million yuan [1]. - The net outflow of main funds was 34.22 million yuan, accounting for 10.33% of the total transaction value, while retail investors saw a net inflow of 14.63 million yuan, representing 4.42% of the total [2]. Company Announcements - Xinmai Medical has repurchased a total of 864,989 shares, with a total expenditure of 91,560,636.42 yuan, intended for employee stock ownership plans or equity incentives [2]. - The company will hold its 2024 annual shareholder meeting on April 18, 2025, to discuss nine agenda items, including the annual report, financial statements, and profit distribution proposals [2][3]. Share Repurchase Program - The initial disclosure of the repurchase plan was on October 30, 2024, with a buyback period from October 28, 2024, to October 27, 2025, and an expected repurchase amount between 100 million yuan and 200 million yuan [3]. - As of March 31, 2025, the repurchased shares accounted for 0.70% of the total share capital, with a repurchase price range between 93.10 yuan and 119.82 yuan per share [3]. - The maximum repurchase price was adjusted to 178.35 yuan per share due to the implementation of the 2024 interim profit distribution [3]. Financial Performance - In 2024, Xinmai Medical reported a revenue of 1.206 billion yuan and a net profit attributable to the parent company of 502 million yuan [3]. - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (including tax), totaling 42.4585 million yuan, and anticipates a mid-2025 profit distribution not exceeding the net profit for the corresponding period [3].